Physician profile
Christopher S Wiggins
NPI 1417581190
$895.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $266 · 2024: $22.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.87 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $165.29 | 2021-2022 | |
| Amarin Pharma, INC. | $163.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.91 | 2021-2022 | |
| Lilly USA, LLC | $30.87 | 2021 | |
| Pfizer INC. | $27.93 | 2021 | |
| Merck Sharp & Dohme LLC | $26.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.22 | 2021-2022 | |
| Novo Nordisk INC | $24.69 | 2021-2022 | |
| Abbott Laboratories | $24.01 | 2022 | |
| Genentech USA, INC. | $17.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.55 | 2022 | |
| Glaxosmithkline, LLC. | $13.38 | 2022 | |
| Organon LLC | $5.04 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.